InsiderTrades

Form 4 for BCRX BIOCRYST PHARMACEUTICALS INC

Accepted 2023-02-02 00:00:00 ET · period of report 2023-02-01 · accession 0001127602-23-003172 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DMI 2023-02-02 2022-12-29 BCRX Stonehouse Jon P Pres, CEO, Dir G - Gift $0.00 +10.0K 10.0K New $0
D 2023-02-02 2023-02-01 BCRX Stonehouse Jon P Pres, CEO, Dir M - OptEx $5.45 +100.0K 1.11M +10% +$545.0K
D 2023-02-02 2023-02-01 BCRX Stonehouse Jon P Pres, CEO, Dir S - Sale+OE $10.38 -100.0K 1.01M -9% -$1.04M
D 2023-02-02 2022-12-29 BCRX Stonehouse Jon P Pres, CEO, Dir G - Gift $0.00 -10.0K 1.01M -1.0% $0
D 2023-02-02 2023-02-01 BCRX Stonehouse Jon P Pres, CEO, Dir M - OptEx $0.00 -100.0K 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-12-29 G A 5,000 $0.00 10,000 I By wife as co-trustee of the Caroline Stonehouse Irrevocable Trust — —
2 Common Common Stock 2022-12-29 G A 5,000 $0.00 10,000 I — —
3 Common Common Stock 2023-02-01 M A 100,000 $5.45 1,108,739 D — —
4 Common Common Stock 2023-02-01 S D 100,000 $10.38 1,008,739 D — — (F3) The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $10.22 to $10.65. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
5 Common Common Stock 2022-12-29 G D 10,000 $0.00 1,008,739 D By wife as co-trustee of the Samuel Stonehouse Irrevocable Trust — —
6 Derivative Emp. Stock Option (Right to Buy) 2023-02-01 M D 100,000 $0.00 0 D $5.45 · — to 2023-08-08 100,000 Common Stock (F4) The options vested upon the achievement of performance-based vesting criteria with respect to 25,000 shares on each of May 26, 2014, December 19, 2014, May 13, 2015 and December 3, 2020.